Amgen announces positive phase-II data for investigational Olpasiran in adults with elevated lipoprotein(a)
The study showed significant and sustained reduction in lipoprotein(a) during treatment period
Amgen recently announced positive data from the phase-II Ocean(a)-Dose clinical study, evaluating Olpasiran (formerly AMG 890) in 281 adult patients with lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interferring RNA designed to lower the body’s production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events, according to a statement by Amgen.
In the double-blind placebo-controlled treatment period, Olpasiran was administered up to 225 mg subcutaneously every 12 weeks to patients with a median baseline